RNO
Director Trades
| Date | Director | Value |
|---|
Company News
Rhinomed develops new-generation nasal swab test for flu and coronavirus
Australian nasal airway and respiratory technology specialist Rhinomed (ASX: RNO) has announced it is developing a new-generation nasal swab capable of collecting samples to test for the presence of upper respiratory tract diseases, including influenza and coronavirus strains. Leveraging the learnings from its Mute (anti-snoring), Pronto (anti-nasal congestion and sleep improvement) and Turbine (improved breathing […]
Rhinomed secures FDA and TGA registration for Pronto vapour release product
Airway technology product developer Rhinomed (ASX: RNO) has secured US Food and Drug Administration and Australian Therapeutic Goods Administration registration for its Pronto vapour release technology. The Pronto rechargeable vapour release unit has now been approved as a class I medical device with both countries’ regulators. Based on Rhinomed’s existing BreatheAssist stenting nasal dilator technology, […]
Rhinomed signs exclusive licensing deal with Columbia Care to advance cannabinoid delivery
Technology company Rhinomed (ASX: RNO) has made an assertive move into the drug delivery market by signing a long-term licensing agreement with the largest provider of cannabis-based products in the US – Columbia Care. Small Caps reported on the deal when it was first announced in mid-September, with the company’s first declaring their partnership as […]
Rhinomed finalising nasal cannabis deal with US developer; expands global distribution network
Australian medical technology company Rhinomed (ASX: RNO) is scheduled to finalise a licensing deal this month with United States-based Columbia Care to develop commercial solutions for nasally-delivered medical cannabis and cannabinoid compounds, analogues and derivatives. A non-binding term sheet signed in June outlined proposed terms for the licensing of Rhinomed’s patented nasal technology platform which […]
Rhinomed partners with largest medical cannabis operator in the US
Australian medical technology company Rhinomed (ASX: RNO) has signed a deal that could see its nasal technology receive accelerated multilateral development and greater adoption in key markets around the world. Rhinomed has signed a non-binding term sheet with the largest US-based medical cannabis operator, Columbia Care LLC. The US giant currently holds licenses in twelve […]
Rhinomed accesses 3,000 pharmacies via new US distribution network deal for novel Mute product
Australian medical technology company Rhinomed (ASX: RNO) will soon be expanding distribution of its proprietary nasal and respiratory solution, Mute, in the United States. The US is currently the world’s leading healthcare market valued at around US$70 billion by industry market analysts. The emergent manufacturer said it has received an “initial opening order” of 6,000 […]
Rhinomed expands footprint in US through 4,300 Walgreens stores
Respiratory technology company Rhinomed Limited (ASX: RNO) has received purchase orders confirming U.S. pharmacy giant Walgreens has core ranged all 4 SKU’s (Trial pack, Small, Medium and Large) of the MUTE sleep and breathing technology in approximately 4,300 pharmacy/drugstores throughout the continental USA. Key Highlights: MUTE expands from 891 to 4,300 Walgreens pharmacy/drug stores. Expansion […]
Company Videos
No videos found.